139 related articles for article (PubMed ID: 37132760)
1. CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas.
Duah E; Seligson ND; Persaud AK; Dam Q; Pabla N; Rocco JW; Li J; Poi M
Mol Carcinog; 2023 Aug; 62(8):1201-1212. PubMed ID: 37132760
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas.
Göttgens EL; Bussink J; Leszczynska KB; Peters H; Span PN; Hammond EM
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):548-558. PubMed ID: 31271827
[TBL] [Abstract][Full Text] [Related]
4. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck.
Billard-Sandu C; Tao YG; Sablin MP; Dumitrescu G; Billard D; Deutsch E
Eur Arch Otorhinolaryngol; 2020 May; 277(5):1273-1280. PubMed ID: 32162057
[TBL] [Abstract][Full Text] [Related]
6. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
van Caloen G; Machiels JP
Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
[TBL] [Abstract][Full Text] [Related]
7. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.
Yang YL; Ji C; Bi ZG; Lu CC; Wang R; Gu B; Cheng L
PLoS One; 2013; 8(1):e54736. PubMed ID: 23372762
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
Robinson AM; Rathore R; Redlich NJ; Adkins DR; VanArsdale T; Van Tine BA; Michel LS
Cell Death Dis; 2019 Nov; 10(11):867. PubMed ID: 31727874
[TBL] [Abstract][Full Text] [Related]
10. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Li C; Johnson DE
Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
[TBL] [Abstract][Full Text] [Related]
11. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
[TBL] [Abstract][Full Text] [Related]
12. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo.
Li R; Wang Q; Zhao Y; Zhu Y; Wang X
Mol Biol Rep; 2024 Mar; 51(1):455. PubMed ID: 38536540
[TBL] [Abstract][Full Text] [Related]
14. Paeoniflorigenone regulates apoptosis, autophagy, and necroptosis to induce anti-cancer bioactivities in human head and neck squamous cell carcinomas.
Park KR; Lee H; Kim SH; Yun HM
J Ethnopharmacol; 2022 Apr; 288():115000. PubMed ID: 35051602
[TBL] [Abstract][Full Text] [Related]
15. Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma.
Hu Q; Peng J; Jiang L; Li W; Su Q; Zhang J; Li H; Song M; Cheng B; Xia J; Wu T
Cell Death Dis; 2020 Oct; 11(10):925. PubMed ID: 33116117
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax.
Gadsden NJ; Fulcher CD; Li D; Shrivastava N; Thomas C; Segall JE; Prystowsky MB; Schlecht NF; Gavathiotis E; Ow TJ
Mol Cancer Res; 2021 May; 19(5):862-873. PubMed ID: 33495400
[TBL] [Abstract][Full Text] [Related]
17. Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status.
Du S; Liu K; Gao P; Li Z; Zheng J
Life Sci; 2018 Nov; 212():182-193. PubMed ID: 30243648
[TBL] [Abstract][Full Text] [Related]
18. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of autophagy enhances the anticancer effect of Schisandrin B on head and neck squamous cell carcinoma.
Li M; Tang Q; Li S; Yang X; Zhang Y; Tang X; Huang P; Yin D
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23585. PubMed ID: 37986106
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
Tai TS; Lin PM; Wu CF; Hung SK; Huang CI; Wang CC; Su YC
Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
